Search Results 1791-1800 of 19646 for hemoglobin

1. Romidepsin in Treating Patients with Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors with Liver Dysfunction - Mayo Clinic

   Hemoglobin ≥ 9 g/dL (transfusions and/or erythropoietin are permitted); Absolute neutrophil count (ANC) ≥ 1.5 x 10^9/L; Platelets ≥ 100 x 10^9/L (or ...

2. A Study to Compare Administering Olaparib Concurrently With Radiotherapy vs. Radiotherapy Alone in Treating Patients With Inflammatory Breast Cancer - Mayo Clinic

   Hemoglobin >= 9.0 g/dL (after transfusion if required and within 28 days prior to registration). Patients must have adequate renal function as evidenced by ...

3. STI-3031 Through Sofusa DoseConnect for Treatment of Intransit Melanoma - Mayo Clinic

   Hemoglobin ≥ 8.0 g/dL;; Absolute neutrophil count (ANC) ≥ 1500/mm^3;; Platelet count ≥ 75,000/mm^3;; Total bilirubin ≤ 1.5 × ULN;; Alanine aminotransferase ...

4. A Study To Evaluate The Effectiveness, Safety, And Tolerability Of BOS-589 In The Treatment Of Patients With Diarrhea-predominant Irritable Bowel Syndrome (IBS-D) - Mayo Clinic

   Hemoglobin A1c level ≥ 8.0% or a confirmed fasting plasma glucose level ≥ 180 mg/dL. Confirmed alanine aminotransferase (ALT) upper limit of normal (ULN) ...

5. Phase 1 Trial to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of Splicing Modulator H3B-8800 for Subjects With Myelodysplastic Syndromes, Acute Myeloid Leukemia, and Chronic Myelomonocytic Leukemia - Mayo Clinic

   ... hemoglobin (Hb) of < 9 g/dL prior to first dose of H3B-8800 (RVT-2001). Subjects who are RBC transfusion-dependent must also have failed erythropoiesis ...

6. ACP-196 in Combination With Pembrolizumab, for Treatment of Hematologic Malignancies - Mayo Clinic

   Thrombocytopenia (platelet count ≤ 100 x 109/L at any time after signing informed consent) OR anemia (hemoglobin ≤ 8.0 g/dL). Subjects who are platelet or ...

7. A Study to Assess the Safety and Tolerability of CFT8634 in Locally Advanced or Metastatic SMARCB1-Perturbed Cancers, Including Synovial Sarcoma and SMARCB1-Null Tumors - Mayo Clinic

   ... hemoglobin ≥ 8 g/dL independent of transfusion support for ≤ 7 days prior to first dose of study drug; platelet count ≥ 75 x 10^9 /L independent of ...

8. A Vaccine (PDS0101) Alone or in Combination With Pembrolizumab for the Treatment of Locally Advanced Human Papillomavirus-Associated Oropharynx Cancer - Mayo Clinic

   - Hemoglobin >= 9.0 g/dL (5.6 mmol/L) (=< 15 days prior to registration) - NOTE: Transfusions are not allowed =< 7 days prior to registration - Total ...

9. Treatment of Genitourinary Syndrome with Platelet Rich Plasma - Mayo Clinic

   - Hemoglobin < 11.6 g/dL or > 15.5 g/dL. If the laboratory reports a single, non-clinically significant result for any of these studies and is the only ...

10. SX-682 Treatment in Subjects With Metastatic Melanoma Concurrently Treated With Pembrolizumab - Mayo Clinic

    Hemoglobin ≥ 9.0 g/dL (may have been transfused);; Creatinine ≤ 1.5 mg/dL;; AST/ALT ≤ 2.5 X ULN for subject with no liver metastases;; ≤ 5 X ULN for ...